Weider Announces Fiscal 2005 Third Quarter Results

SALT LAKE CITY, Apr 04, 2005 (BUSINESS WIRE) -- Weider Nutrition International, Inc. (WNI) today announced results for the fiscal 2005 third quarter and nine-months ended February 28, 2005.

Weider Nutrition's net sales were $65.6 million for the third quarter, compared to $67.5 million for the same period in fiscal 2004. For its fiscal 2005 third quarter, Weider Nutrition reported net income of $1.2 million, or $0.05 per share, compared to $2.6 million, or $0.10 per share, for the same period a year ago.

Weider Nutrition's net sales were $202.3 million for the nine-months ended February 28, 2005, compared to $191.9 million for the same period in fiscal 2004. For the first nine months of fiscal 2005, Weider Nutrition reported net income of $8.4 million, or $0.32 per share, compared to $7.4 million, or $0.28 per share, for the same period a year ago.

Bruce Wood, president and chief executive officer stated, "We experienced a modest decrease in third quarter sales over the year-ago period. The reduction is primarily a function of a decline in domestic private label sales, as well as weakness in our Haleko business unit's Multipower(R) and Multaben brands. However, we are continuing to invest in branded growth initiatives, most notably the ongoing introduction of our Schiff Lubriflex3(TM) premium joint care entry."

Wood continued, "We also experienced a reduction in our gross margin and operating margin percentages. Operating results were negatively impacted by volatile raw material costs in our joint care business, increased marketing spending in support of new products, and disappointing Haleko branded sales. We expect higher raw material costs, significant marketing support behind Lubriflex3 and the continued challenging competitive environment in Germany to continue into fiscal 2006. Nevertheless, we remain committed to a long-term strategy of strengthening our brands in what continues to be a very competitive and compressed margin marketplace, and our strong balance sheet provides us with resources to support this strategy."

About Weider Nutrition

Weider Nutrition International, Inc. develops, manufactures, markets and sells branded and private label vitamins, nutritional supplements and sports nutrition products in the United States and throughout the world. To learn more about Weider, please visit the Web site www.weider.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended, that are based on management's beliefs and assumptions, current expectations, estimates, and projections. These statements are subject to risks and uncertainties, certain of which are beyond the company's ability to control or predict, and, therefore, actual results may differ materially. Weider Nutrition disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.

Important factors that may cause these forward looking statements to be false include, but are not limited to: the inability to successfully implement marketing and spending programs behind our Move Free brand and other branded new products, the inability to successfully launch and gain distribution for our Schiff Lubriflex3 product and Schiff Move Free product enhancements, raw material pricing and availability particularly in the joint care category, and the inability to pass on raw material price increases to customers, dependence on, and availability of, raw materials from China, dependence on individual products, the inability to achieve cost savings and operational efficiencies, the inability to increase operating margins and increase revenues, the inability to successfully relaunch brands in our Haleko Unit, dependence on individual customers, the impact of competitive products and pricing (including private label), market and industry conditions (including pricing, demand for products and level of trade inventories), the success of product development, the inability to obtain customer acceptance of new product introductions, changes in laws and regulations, including proposed FDA good manufacturing practices, litigation and government regulatory action, lack of available product liability insurance for products containing ephedra, adverse publicity regarding the consumption of nutritional supplements, changes in accounting standards, and other factors indicated from time to time in the company's SEC reports, copies of which are available upon request from the company's investor relations department or may be obtained at the SEC's website (www.sec.gov).

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.